Target Pattern Recognition by Complement Proteins of the Classical and Alternative Pathways

  • Yu-Hoi Kang
  • Lee Aun Tan
  • Maria V. Carroll
  • Madeleine E. Gentle
  • Robert B. Sim
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 653)


The complement system is a major component of the innate defence of animals against invading microorganisms, and is also essential for the recognition and clearance of damaged or structurally-altered host cells or macromolecules. The system is activated by three different pathways, each of which responds, using different recognition molecules, to a very wide range of activators. The recognition protein of the complement classical pathway, C1q is described in detail here, with comparisons to the alternative pathway.


Complement Activation Classical Pathway Complement Protein Human Complement Complement Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058–1066.CrossRefPubMedGoogle Scholar
  2. 2.
    Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140–1144.CrossRefPubMedGoogle Scholar
  3. 3.
    Mayilyan KR, Kang YH, Dodds AW et al. The complement system in innate immunity. In: Heine H, ed. Innate Immunity of Plants, Animals and Humans (Nucleic acids and molecular biology vol 21). Heidelberg: Springer, 2008:219–236.CrossRefGoogle Scholar
  4. 4.
    Sim RB, Dodds AW The complement system: an introduction. In Dodds AW, Sim RB, eds. Complement, a Practical Approach. Oxford: Oxford University Press, 1997:1–18.Google Scholar
  5. 5.
    Sim RB, Reid KBM. C1: Molecular interaction with activating systems. Immunol Today 1991; 12:307–311.CrossRefPubMedGoogle Scholar
  6. 6.
    Sim RB, Malhotra R. Interactions of carbohydrates and lectins with complement. Biochem Soc Trans 1994; 22:106–111.PubMedGoogle Scholar
  7. 7.
    Dodds AW, Sim RB, Porter RR et al. Activation of the first component of human complement (C1) by antibody-antigen aggregates. Biochem J 1978; 175:383–390.PubMedGoogle Scholar
  8. 8.
    Krarup A, Mitchell DA, Sim RB. Recognition of acetylated oligosaccharides by human L-ficolin. Immunol Lett 2008; 118:52–56.CrossRefGoogle Scholar
  9. 9.
    Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans 2004; 32:21–27.CrossRefPubMedGoogle Scholar
  10. 10.
    Kemper C, Hourcade DE. Properdin: New roles in pattern recognition and target clearance. Mol Immunol 2008; 45:4048–4056.CrossRefPubMedGoogle Scholar
  11. 11.
    Sim RB, Moffatt BE, Shaw JM et al. Complement control proteins and receptors: from FH to CR4. In: Reid KB, Sim RB, eds. Molecular Aspects of Innate and Adaptive Immunity. Cambridge: Royal Society of Chemistry, 2008:84–104.CrossRefGoogle Scholar
  12. 12.
    Reid KB, Porter RR. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J 1976, 155:19–23.PubMedGoogle Scholar
  13. 13.
    Knobel HR, Villiger W, Isliker H. Chemical analysis and electron microscopy studies of human C1q prepared by different methods. Eur J Immunol 1975; 5:78–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Reid KB, Sim RB, Faiers AP. Inhibition of the reconstitution of the haemolytic activity of the rirst component of human complement by a pepsin-derived fragment of subcomponent C1q. Biochem J 1977; 161:239–245.PubMedGoogle Scholar
  15. 15.
    Sim RB, Arlaud GJ, Colomb MG. C1-inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem J 1979; 179:449–457.PubMedGoogle Scholar
  16. 16.
    Sim RB, Arlaud GJ, Colomb MG. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta 1980; 612:433–449.PubMedGoogle Scholar
  17. 17.
    Colten HR, Gordon JM, Borsos T et al. Synthesis of the first component of human complement in vitro. J Exp Med 1968; 128:595–603.CrossRefPubMedGoogle Scholar
  18. 18.
    Morris KM, Colten HR, Bing DH. The first component of complement. A quantitative comparison of its biosynthesis in culture by human epithelial and mesenchymal cells. J Exp Med 1978; 148:1007–1014.CrossRefPubMedGoogle Scholar
  19. 19.
    Schwaeble W, Schafer MK, Petry F et al. Follicular dendritic cells, interdigitaring cells, and cells of the monocyte-macrophage lineage are the C1q-producing sources in the spleen. Identification of specific cell types by in situ hybridization and immunohistochemical analysis. J Immunol 1995; 155:4971–4977.PubMedGoogle Scholar
  20. 20.
    Whaley K. Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 1980; 151:501–514.CrossRefPubMedGoogle Scholar
  21. 21.
    Gulati P, Lemercier C, Guc D et al. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. Behring Inst Mitt 1993; 93:196–203.PubMedGoogle Scholar
  22. 22.
    Tseng Y, Zavodszky P, Schumaker VN. The human complement C1 complex has a picomolar dissociation constant at room temperature. J Immunol 1997; 158:937–944.PubMedGoogle Scholar
  23. 23.
    Schumaker VN, Zavodszky P, Poon PH. Activation of the first component of complement. Annu Rev Immunol 1987; 5:21–42.CrossRefPubMedGoogle Scholar
  24. 24.
    Bindon CI, Hale G, Waldmann H. Complement activation by immunoglobulin does not depend solely on C1q binding. Eur J Immunol 1990; 20:277–281.CrossRefPubMedGoogle Scholar
  25. 25.
    Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507–1514.CrossRefPubMedGoogle Scholar
  26. 26.
    Brüggemann M, Williams GT, Bindon CI et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351–1361.CrossRefPubMedGoogle Scholar
  27. 27.
    Sim RB ed. Activators and Inhibitors of Complement. Dordrecht: Kluwer, 1993.Google Scholar
  28. 28.
    Roumenina L, Bureeva S, Kantardjiev A et al. Complement C1q-target proteins recognition is inhibited by electric moment effectors. J Mol Recognit 2007; 20:405–415.CrossRefPubMedGoogle Scholar
  29. 29.
    Arnold JN, Wormald MR, Sim RB et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21–50.CrossRefPubMedGoogle Scholar
  30. 30.
    Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332:738–742.CrossRefPubMedGoogle Scholar
  31. 31.
    Idusogie EE, Presta LG, Gazzano-Santoro H et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178–4184.PubMedGoogle Scholar
  32. 32.
    Perkins S J, Nealis AS, Sutton BJ et al. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol 1991; 221:1345–1366.CrossRefPubMedGoogle Scholar
  33. 33.
    Païdassi H, Tacnet-Delorme P, Lunardi T et al. The lectin-like activity of human C1q and its implication in DNA and apoptotic cell recognition. FEBS Lett 2008; 582:3111–3116.CrossRefPubMedGoogle Scholar
  34. 34.
    Loos M, Bitter-Suermann D, Dierich MP. Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol 1974; 112:935–950.PubMedGoogle Scholar
  35. 35.
    Zohair A, Chesne S, Wade RH et al. Interaction between complement subcomponent C1q and bacterial lipopolysaccharides. Biochem J 1989; 257:865–873.PubMedGoogle Scholar
  36. 36.
    Latsch M, Möllerfeld J, Ringsdorf H et al. Studies on the interaction of C1q, a subcomponent of the first component of complement, with porins from Salmonella minnesota incorporated into artificial membranes. FEBS Lett 1990; 276:201–204.CrossRefPubMedGoogle Scholar
  37. 37.
    Van Schravendijk MR, Dwek RA. Interaction of C1q with DNA. Mol Immunol 1982; 19:1179–1184.CrossRefPubMedGoogle Scholar
  38. 38.
    Kovacsovics T, Tschopp J, Kress A et al. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J Immunol 1985; 135:2695–2703.PubMedGoogle Scholar
  39. 39.
    Tan LA, Sim RB. Complement activation by phospholipids (PL). Mol Immunol 2001; 38:122–122.Google Scholar
  40. 40.
    Païdassi H, Tacnet-Delorme P, Garlatti V et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 2008; 180:2329–2338.PubMedGoogle Scholar
  41. 41.
    Sorensen IJ, Nielsen EH, Andersen O et al 1996. Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol 1996; 44:401–409.CrossRefPubMedGoogle Scholar
  42. 42.
    McGrath FD, Brouwer MC, Arlaud GJ et al. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 2006; 176:2950–2957.PubMedGoogle Scholar
  43. 43.
    Agrawal A, Shrive AK, Greenhough TJ et al. Topology and structure of the C1q-binding site on C-reactive protein. J Immunol 2001; 166:3998–4004.PubMedGoogle Scholar
  44. 44.
    Bickerstaff MC, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5:694–697.CrossRefPubMedGoogle Scholar
  45. 45.
    Hicks PS, Saunero-Nava L, Du Clos TW et al. Serum amyloid P component binds to histories and activates the classical complement pathway. J Immunol 1992; 149:3689–3694.PubMedGoogle Scholar
  46. 46.
    Boackle RJ, Connor MH, Vesely J. High molecular weight nonimmunoglobulin salivary agglutinins (NLA) bind C1Q globular heads and have the potential to activate the first complement component. Mol Immunol 1993; 30:309–319.CrossRefPubMedGoogle Scholar
  47. 47.
    Ebenbichler CF, Thielens NM, Vornhagen M et al 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174:1417–1424.CrossRefPubMedGoogle Scholar
  48. 48.
    Loos M, Clas F, Fischer W. Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun 1986; 53:595–599.PubMedGoogle Scholar
  49. 49.
    Carroll MV, Lack N, Krarup A et al. Multiple routes of complement activation by mycobacterium bovis BCG. Molec Immunol 2008; 45:4168–4168.CrossRefGoogle Scholar
  50. 50.
    Sim RB, Kishore U, Villiers CL et al. C1q binding and complement activation by prions and amyloids. Immunobiology 2007; 212:355–362.CrossRefPubMedGoogle Scholar
  51. 51.
    Salvador-Morales C, Flahaut E, Sim E et al. Carbon nanotubes activate the human serum complement system. Molec Immunol 2006; 43:193–201.CrossRefGoogle Scholar
  52. 52.
    Nilsson UR, Lam O, Nilsson B et al. Modification of the complement binding properties of polystyrene: effects of end-point heparin attachment. Scand J Immunol 1993; 37:349–354.CrossRefPubMedGoogle Scholar
  53. 53.
    Cliquet F, Cuillière ML, Montagne P et al. Interactions of complement fraction C1q, fibronectin, and immunoglobulin G with polyacrylic microparticles used as solid-phase in immunoassay. J Biomed Mater Res 1993; 27:587–597.CrossRefPubMedGoogle Scholar
  54. 54.
    Hamad OA, Ekdahl KN, Nilsson PH et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6:1413–1421.CrossRefPubMedGoogle Scholar
  55. 55.
    Kirschfink M, Blase L, Engelmann S et al. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J Immunol 1997; 158:1324–1331.PubMedGoogle Scholar
  56. 56.
    Almeda S, Rosenberg RD, Bing DH. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem 1983; 258:785–791.PubMedGoogle Scholar
  57. 57.
    Krumdieck R, Höök M, Rosenberg LC et al. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol 1992; 149:3695–3701.PubMedGoogle Scholar
  58. 58.
    Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131:1164–1178.CrossRefPubMedGoogle Scholar
  59. 59.
    Mayilyan KR, Weinberger DR, Sim RB. The complement system in schizophrenia. Drug News Perspect 2008; 21:200–210.CrossRefPubMedGoogle Scholar
  60. 60.
    Navratil JS, Watkins SC, Wisnieski JJ et al. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol 2001; 166:3231–3238.PubMedGoogle Scholar
  61. 61.
    Nauta AJ, Trouw L, Daha MR et al 2002. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002; 32:1726–1732.CrossRefPubMedGoogle Scholar
  62. 62.
    Ogden CA, deCathelineau A, Hoffmann PR et al 2001. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194:781–790.CrossRefPubMedGoogle Scholar
  63. 63.
    Nauta AJ, Castellano G, Xu W et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 173:3044–3050.PubMedGoogle Scholar
  64. 64.
    Nauta AJ, Daha MR, van Kooten C et al. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003; 24:148–153.CrossRefPubMedGoogle Scholar
  65. 65.
    Pickering MC, Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76:227–240.CrossRefPubMedGoogle Scholar
  66. 66.
    Botto M, Dell’Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19:56–59.CrossRefPubMedGoogle Scholar
  67. 67.
    Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317–1324.CrossRefPubMedGoogle Scholar
  68. 68.
    Gaboriaud C, Juanhuix J, Gruez A et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 2003; 278:46974–46980.CrossRefPubMedGoogle Scholar
  69. 69.
    Corpet F. Multiple sequence alignment with hierarchical clustering. Nucl Acids Res 1988; 16:10881–10890.CrossRefPubMedGoogle Scholar
  70. 70.
    Kishore U, Strong P, Perdikoulis MV et al. A recombinant homotrimer, composed of the alpha helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway. J Immunol 2001; 166:559–565.PubMedGoogle Scholar
  71. 71.
    Kishore U, Leigh LE, Eggleton P et al. Functional characterization of a recombinant form of the C-terminal, globular head region of the B-chain of human serum complement protein, C1q. Biochem J 1998; 333:27–32.PubMedGoogle Scholar
  72. 72.
    Kishore U, Gupta SK, Perdikoulis MV et al. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. J Immunol 2003; 171:812–820.PubMedGoogle Scholar
  73. 73.
    Kojouharova MS, Gadjeva MG, Tsacheva IG et al. Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for argininc and histidine residues in the C1q-IgG interaction. J Immunol 2004; 172:4351–4358.PubMedGoogle Scholar
  74. 74.
    Roumenina LT, Ruseva MM, Zlatarova A et al. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 2006; 45:4093–4104.CrossRefPubMedGoogle Scholar
  75. 75.
    Gadjeva MG, Rouseva MM, Zlatarova AS et al. Interaction of Human C1q with IgG and IgM: Revisited. Biochemistry 2008; 47(49): 13093–14002.CrossRefPubMedGoogle Scholar
  76. 76.
    Roumenina LT, Kantardjiev AA, Atanasov BP et al. Role of Ca2+ in the electrostatic stability and the functional activity of the globular domain of human C1q. Biochemistry 2005; 44:14097–15009.CrossRefPubMedGoogle Scholar
  77. 77.
    Sim, RB, Moestrup SK, Stuart GR et al. Interaction of C1q and the collectins with the potential receptors calreticulin (cC1qR/collectin receptor) and megalin. Immunobiology 1998; 199:208–215.PubMedGoogle Scholar
  78. 78.
    Malhotra R, Thiel S, Reid KB et al. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med 1990; 172:955–959.CrossRefPubMedGoogle Scholar
  79. 79.
    Malhotra R, Laursen SB, Willis AC et al Localization of the receptor-binding site in the collectin family of proteins. Biochem J 1993; 293:15–19.PubMedGoogle Scholar
  80. 80.
    Guan E, Robinson SL, Goodman EB et al. Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J Immunol 1994; 152:40054011.Google Scholar
  81. 81.
    McGreal E., Ikewaki N, Akatsu H et al. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. J Immunol 2002; 168:5222–5228.PubMedGoogle Scholar
  82. 82.
    Klickstein L, Barbashov SF, Liu T et al. Complement receptor type 1 (CRI, CD35) is a receptor for C1q. Immunity 1997; 7:345–353.CrossRefPubMedGoogle Scholar
  83. 83.
    van den Berg RH., Faber-Krol MC, Sim RB et al 1998. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J Immunol 1998; 161:6924–6931.PubMedGoogle Scholar
  84. 84.
    Dodds AW. The evolution of complement systems. In: Reid KB, Sim RB, eds. Molecular Aspects of Innate and Adaptive Immunity. Cambridge: Royal Society of Chemistry, 2008:27–48.CrossRefGoogle Scholar
  85. 85.
    Matsushita M, Matsushita A, Endo Y et al. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin. Proc Natl Acad Sci USA 2004; 101:10127–10131.CrossRefPubMedGoogle Scholar
  86. 86.
    Yu Y, Huang H, Wang Y et al. A novel C1q family member of amphioxus was revealed to have a partial function of vertebrate C1q molecule. J Immunol 2008; 181:7024–7032.PubMedGoogle Scholar
  87. 87.
    Nolan KF, Schwaeble W, Kaluz S et al Molecular cloning of the cDNA coding for properdin, a positive regulator of the alternative pathway of human complement. Eur J Immunol 1991; 21:771–776.CrossRefPubMedGoogle Scholar
  88. 88.
    Schwaeble W, Reid KB. Does properdin crosslink the cellular and the humoral immune response? Immunol Today 1999; 20:17–21.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Yu-Hoi Kang
    • 2
  • Lee Aun Tan
    • 3
    • 4
  • Maria V. Carroll
    • 3
    • 5
  • Madeleine E. Gentle
    • 3
    • 4
  • Robert B. Sim
    • 1
  1. 1.Department of PharmacologyOxford UniversityOxfordUK
  2. 2.MRC Immunochemistry Unit Department of PharmacologyUniversity of OxfordOxfordUK
  3. 3.MRC Immunochemistry Unit Department of BiochemistryUniversity of OxfordOxfordUK
  4. 4.Division of Cell and Molecular BiologyImperial College LondonLondonUK
  5. 5.Department of PharmacologyUniversity of OxfordOxfordUK

Personalised recommendations